

1/13




FIG. 1

2/13




FIG. 2

3/13




FIG. 3

4/13

306




FIG. 4

5/13




FIG. 5






FIG. 6


7/13



8/13



9/13



EVENTS STREAM 1					
EVENTS	ANTICIPATED DATE OF OCCURRENCE	EVIDENCE OF OCCURRENCE	EVIDENCE OF		DESIGNATED OBSERVERS
			INCREASING LIKELIHOOD	DECREASING LIKELIHOOD	




FIG. 9

10/13




FIG. 10




FIG. 11

11/13




FIG. 12

12/13

CALCULATION OF OUTCOME VARIANCE

PV OF BIO-TECH DRUG PROJECTS	468.999
PV OF BIO-INFORMATICS TOOLS	134.424
FREE CASH PV	2.649
CURRENT PV OF GREENGENE	600.774
LAST YEAR'S PV	471.418
DELTA_PV	129.356
CoCr ON LAST YR PV	75.427
OUTCOME VARIANCE	53.929

ANALYSIS OF OUTCOME VARIANCE

CAUSE	EFFECT \$ MLNS
REVISED PROJECTION TOOL #4 SALES	
FROM 0.017% TO 0.015%	25.009
WORLD BIO-TECH SALES GROWTH THRU 2005	
FROM 11.5% TO 12.5%	14.931
REVISED PROJECTION DRUG #26 SALES	
FROM 0.45% TO 0.70%	10.196
LAST YR WORLD SALES GREW 12.9% NOT 11.5%	7.000
INCREASED R&D SPENDING LAST YEAR	-1.607
INCREASED FUTURE R&D SPENDING	-1.461
EFFECT OF WHO DONATION	-0.306
LAST YR'S INVESTMENT INCOME BETTER	0.167
	53.929

FIG. 13

